Recalibration and validation of the Charlson Comorbidity Index in acute kidney injury patients underwent continuous renal replacement therapy

다국어 초록 (Multilingual Abstract)

Background: Comorbid conditions impact the survival of patients with severe acute kidney injury (AKI) who require continuous renal replacement therapy (CRRT). The weights assigned to comorbidities in predicting survival vary based on type of index, disease, and advances in management of comorbidities. We developed a modified Charlson Comorbidity Index (CCI) for use in patients with AKI requiring CRRT (mCCI-CRRT) and improved the accuracy of risk stratification for mortality. Methods: A total of 828 patients who received CRRT between 2008 and 2013, from three university hospital cohorts was included to develop the comorbidity score. The weights of the comorbidities were recalibrated using a Cox proportional hazards model adjusted for demographic and clinical information. The modified index was validated in a university hospital cohort (n = 919) using the data of patients treated from 2009 to 2015. Results: Weights for dementia, peptic ulcer disease, any tumor, and metastatic solid tumor were used to recalibrate the mCCI-CRRT. Use of these calibrated weights achieved a 35.4% (95% confidence interval [CI], 22.1%–48.1%) higher performance than unadjusted CCI in reclassification based on continuous net reclassification improvement in logistic regression adjusted for age and sex. After additionally adjusting for hemoglobin and albumin, consistent results were found in risk reclassification, which improved by 35.9% (95% CI, 23.3%–48.5%). Conclusion: The mCCI-CRRT stratifies risk of mortality in AKI patients who require CRRT more accurately than does the original CCI, suggesting that it could serve as a preferred index for use in clinical practice.

참고문헌 (Reference)

1 Sakr Y, "The influence of gender on the epidemiology of and outcome from severe sepsis" 17 : R50-, 2013

2 Ortiz Librero M, "The importance of comorbidity in nephrologists’ assessment of acute renal failure" 29 : 430-438, 2009

3 Danai PA, "The epidemiology of sepsis in patients with malignancy" 129 : 1432-1440, 2006

4 Cook DJ, "The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients" 5 : 368-375, 2001

5 Zettersten E, "Sex and gender aspects on intensive care : a cohort study" 55 : 22-27, 2020

6 Rutherford AI, "Serious infection across biologic-treated patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis" 77 : 905-910, 2018

7 George MD, "Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty" 171 : 680-, 2019

8 Cook DJ, "Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group" 330 : 377-381, 1994

9 Pinheiro KH, "Risk factors and mortality in patients with sepsis, septic and non septic acute kidney injury in ICU" 41 : 462-471, 2019

10 Park JY, "Recalibration and validation of the Charlson comorbidity index in Korean incident hemodialysis patients" 10 : e0127240-, 2015

11 Schuster DP, "Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit" 76 : 623-630, 1984

12 Bagshaw SM, "Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure : a population-based study" 9 : R700-R709, 2005

13 Krag M, "Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients" 41 : 833-845, 2015

14 Krag M, "Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU" 379 : 2199-2208, 2018

15 Shingarev R, "Kidney complications of immune checkpoint inhibitors : a review" 74 : 529-537, 2019

16 Vallabhaneni S, "Fungal infections and new biologic therapies" 18 : 29-, 2016

17 Halligan S, "Disadvantages of using the area under the receiver operating characteristic curve to assess imaging tests : a discussion and proposal for an alternative approach" 25 : 932-939, 2015

18 Thirumala R, "Diagnosis and management of infectious complications in critically ill patients with cancer" 26 : 59-91, 2010

19 Cho H, "Development and validation of the modified Charlson Comorbidity Index in incident peritoneal dialysis patients : a national population-based approach" 37 : 94-102, 2017

20 Rosolem MM, "Critically ill patients with cancer and sepsis : clinical course and prognostic factors" 27 : 301-307, 2012

21 Prowle JR, "Continuous renal replacement therapy : recent advances and future research" 6 : 521-529, 2010

22 Fried L, "Comparison of the Charlson Comorbidity Index and the Davies score as a predictor of outcomes in PD patients" 23 : 568-573, 2003

23 Miskulin DC, "Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial" 60 : 1498-1510, 2001

24 Athienites NV, "Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease" 13 : 320-326, 2000

25 Park JY, "Comorbidities can predict mortality of kidney transplant recipients : comparison with the Charlson Comorbidity Index" 50 : 1068-1073, 2018

26 Wanchoo R, "Adverse renal effects of immune checkpoint inhibitors : a narrative review" 45 : 160-169, 2017

27 Uchino S, "Acute renal failure in critically ill patients : a multinational, multicenter study" 294 : 813-818, 2005

28 Chertow GM, "Acute kidney injury, mortality, length of stay, and costs in hospitalized patients" 16 : 3365-3370, 2005

29 Rosner MH, "Acute kidney injury in patients with cancer" 376 : 1770-1781, 2017

30 Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation" 40 : 373-383, 1987